| Guidelines for the use and interpretation of assays for monitoring autophagy DJ Klionsky, FC Abdalla, H Abeliovich, RT Abraham, A Acevedo-Arozena, ... Autophagy 8 (4), 445-544, 2012 | 13712* | 2012 |
| Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer A Leonetti, S Sharma, R Minari, P Perego, E Giovannetti, M Tiseo British journal of cancer 121 (9), 725-737, 2019 | 1056 | 2019 |
| MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity E Giovannetti, N Funel, GJ Peters, M Del Chiaro, LA Erozenci, E Vasile, ... Cancer research 70 (11), 4528-4538, 2010 | 533 | 2010 |
| Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine E Giovannetti, M Del Tacca, V Mey, N Funel, S Nannizzi, S Ricci, ... Cancer research 66 (7), 3928-3935, 2006 | 438 | 2006 |
| Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer JH Hwang, J Voortman, E Giovannetti, SM Steinberg, LG Leon, YT Kim, ... PloS one 5 (5), e10630, 2010 | 363 | 2010 |
| Analysis of drug interactions IV Bijnsdorp, E Giovannetti, GJ Peters Cancer Cell Culture: Methods and Protocols, 421-434, 2011 | 293 | 2011 |
| Tyrosine kinase inhibitors: Multi-targeted or single-targeted? F Broekman, E Giovannetti, GJ Peters World journal of clinical oncology 2 (2), 80, 2011 | 288 | 2011 |
| Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets MG Best, N Sol, S GJG, A Vancura, M Muller, ALN Niemeijer, AV Fejes, ... Cancer cell 32 (2), 238-252. e9, 2017 | 279 | 2017 |
| Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin–treated advanced non–small cell lung cancer patients C Tibaldi, E Giovannetti, E Vasile, V Mey, AC Laan, S Nannizzi, ... Clinical cancer research 14 (6), 1797-1803, 2008 | 273 | 2008 |
| Platinum-induced neurotoxicity and preventive strategies: past, present, and future A Avan, TJ Postma, C Ceresa, A Avan, G Cavaletti, E Giovannetti, ... The oncologist 20 (4), 411-432, 2015 | 271 | 2015 |
| Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells C Granchi, S Roy, C Giacomelli, M Macchia, T Tuccinardi, A Martinelli, ... Journal of medicinal chemistry 54 (6), 1599-1612, 2011 | 271 | 2011 |
| Drug resistance in pancreatic cancer: Impact of altered energy metabolism C Grasso, G Jansen, E Giovannetti Critical reviews in oncology/hematology 114, 139-152, 2017 | 243 | 2017 |
| Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non–small-cell lung cancer cells E Giovannetti, V Mey, S Nannizzi, G Pasqualetti, L Marini, M Del Tacca, ... Molecular pharmacology 68 (1), 110-118, 2005 | 239 | 2005 |
| Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective J Ciccolini, C Serdjebi, GJ Peters, E Giovannetti Cancer chemotherapy and pharmacology 78, 1-12, 2016 | 219 | 2016 |
| Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice E Giovannetti, A Erozenci, J Smit, R Danesi, GJ Peters Critical reviews in oncology/hematology 81 (2), 103-122, 2012 | 212 | 2012 |
| Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9 E Rodriguez, K Boelaars, K Brown, RJ Eveline Li, L Kruijssen, ... Nature communications 12 (1), 1270, 2021 | 202 | 2021 |
| The role of alternative splicing in cancer: From oncogenesis to drug resistance R Sciarrillo, A Wojtuszkiewicz, YG Assaraf, G Jansen, GJL Kaspers, ... Drug Resistance Updates 53, 100728, 2020 | 202 | 2020 |
| Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate … E Giovannetti, C Lemos, C Tekle, K Smid, S Nannizzi, JA Rodriguez, ... Molecular pharmacology 73 (4), 1290-1300, 2008 | 201 | 2008 |
| MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression AE Frampton, L Castellano, T Colombo, E Giovannetti, J Krell, J Jacob, ... Gastroenterology 146 (1), 268-277. e18, 2014 | 189 | 2014 |
| Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia M Maftouh, A Avan, R Sciarrillo, C Granchi, LG Leon, R Rani, N Funel, ... British journal of cancer 110 (1), 172-182, 2014 | 184 | 2014 |
GJ PetersProfessor of Pharmacology of Cytostatics, Amsterdam UMC, location VUMC, Amsterdam; and MedicalVerified email at amsterdamumc.nl
